To our knowledge, seven studies have included both CRP and PA in the prognostication of DLBCL [14–20], but only one assessed whether these contributed to the discriminatory ability of globally accepted prognostic DLBCL indices [17]. The gene discussed is CRP; the disease is diffuse large B-cell lymphoma.